28.01.2020 • NewsElaine BurridgeErgomedPharmacovigilance

Ergomed Acquires Ashfield Pharmacovigilance

Ergomed Acquires Ashfield Pharmacovigilance (c) Ergomed
Ergomed Acquires Ashfield Pharmacovigilance (c) Ergomed

UK clinical development organization Ergomed has paid $10 million cash to buy Ashfield Pharmacovigilance, a US-based specialist pharmacovigilance services provider based at Cary in the North Carolina Research Triangle. Seller is UDG Healthcare.

Ergomed said the acquisition supports its drive to further develop its broader combined clinical research and pharmacovigilance business globally and provides a platform for potential further growth in North America.

For Miroslav Reljanovic, Ergomed’s executive chairman, the purchase of Ashfield is “a major step forward in the strategically important US market”. He commented: “It provides a significant US pharmacovigilance presence and access to a genuinely global offering for customers.

Relijanovic added that the buy also strengthens the US platform for the Ergomed clinical research organization’s business as it continues it drive toward becoming a leading mid-tier pharmaceutical services specialist with a global presence.

Ashfield, founded as Drug Safety Alliance in 2000 and acquired by UDG in 2012, will now become part of Ergomed’s PrimeVigilance division. In the fiscal year ending Sep. 30 2019, Ashfield reported revenues of $11.6 million and adjusted EBITDA of $900,000, with net assets of $2.8 million. Its order book stood at $9.8 million.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read